LUNG
NASDAQ
$1.36
Pulmonx Corp (LUNG)
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
Sector:
Healthcare
Industry:
Medical Devices
Buy
Target: $3.40 (+150.92%)
Market Cap
$61M
Revenue 5Y CAGR
+21.56%
Free Cash Flow Yield
-48.36%
Beta (5Y)
1.06
Price Chart
Valuation
Market Cap$61M
Forward P/E28.33
P/S0.69
P/B1.37
Profitability
Total Revenue (TTM)$89M
Gross Profit (TTM)$67M
EBITDA-$51M
Profit Margin-66.3%
Operating Margin-62.9%
EPS-$1.28
Financial Health
Debt-to-Equity81.5%
Free Cash Flow Yield-48.36%
Growth & Risk
Revenue 5Y CAGR+21.56%
FCF 5Y CAGR-1.38%
Beta (5Y)1.06
Sharpe Ratio-0.37